💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Metronidazole

CHEMBL137 Phase 4 Approuvé Small molecule
Half-Life
8 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
171.2 g/mol
LogP
—
Phase
4

This antibiotic and antiprotozoal drug kills bacteria and parasites by damaging their DNA. It is used to treat a wide range of infections including those of the digestive tract, reproductive system, and skin.

Masse moléculaire

171,1540 g/mol

LogP

0,00

TPSA

83,90 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Endometriosis Glaucoma Cardiovascular Disease Age-Related Macular Degeneration Pain Management Ophthalmology Non-Small Cell Lung Cancer Asthma Chronic Obstructive Pulmonary Disease Immunology Parkinson's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Infectious Disease Melanoma Oncology Inflammatory Bowel Disease Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Obesity Lymphoma Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer Chronic Pain Malaria HIV/AIDS Tuberculosis Heart Failure Atrial Fibrillation Prostate Cancer Colorectal Cancer Leukemia

Classes de médicaments

J — J - Antiinfectives for Systemic Use

Mécanisme d'action

Forms cytotoxic free radicals that damage bacterial DNA.

Pharmacokinetics (PK)

Half-Life 8 hours

Pharmacodynamics (PD)

Mécanisme

Forms cytotoxic free radicals that damage bacterial DNA.

Structure 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1ncc([N+](=O)[O-])n1CCO

                

                

                
                

                    
InChI

                    
InChI=1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C6H9N3O3

                    

                    
                    

                        
HBD / HBA

                        
1 / 4

                    

                    
                    

                        
Liaisons Rotatives

                        
2

                    

                    
                    
                    

                        
Atomes Lourds

                        
12

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            CYP2D6 (Cytochrome P450 2D6)
                            Inhibitor
                        

                        
                        Primary Target
                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Major


                            
                                Metronidazole + Warfarin
                            
                        

                        
                        
Metronidazole markedly potentiates warfarin anticoagulation, leading to supratherapeutic INR levels and an elevated risk of serious bleeding.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Foire aux questions

                

                    
                    

                        
                        

                            
This antibiotic and antiprotozoal drug kills bacteria and parasites by damaging their DNA. It is used to treat a wide range of infections including those of the digestive tract, reproductive system, and skin.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Forms cytotoxic free radicals that damage bacterial DNA.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Metronidazole: Half-life: 8 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Metronidazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Amoxicillin
                            Small molecule
                        
                        
                        
                            Azithromycin
                            Small molecule
                        
                        
                        
                            Ciprofloxacin
                            Small molecule
                        
                        
                        
                            Doxycycline
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL137.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 4173.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Avertissement médical

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.